Incorrect Use of Process Validation Tools Led to FDA Warning Letters
This article was originally published in The Gold Sheet
Manufacturers have been learning the hard way not to use fancy statistical tools for process validation without really understanding them. Inappropriate sampling plans, Cpk analyses, defect/complaint rate analyses and other such failures recently triggered FDA warning letters.
You may also be interested in...
US HHS turns to COVID-19 vaccine distributor to assemble vaccine administration kits, citing revised vaccine delivery schedule.
Stand-alone bill headed for Senate, where it fared poorly in coronavirus response legislative packages.
Agency begins gathering manufacturing plant data to prepare for disruptions that can drain inventories over a weekend.